Stay updated on PANDORE Clinical Trial: Pembrolizumab in Bladder Cancer
Sign up to get notified when there's something new on the PANDORE Clinical Trial: Pembrolizumab in Bladder Cancer page.

Latest updates to the PANDORE Clinical Trial: Pembrolizumab in Bladder Cancer page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated to v3.4.2. Previous notices, including the government funding lapse notice and Revision: v3.4.1, were removed.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a government funding lapse notice at the top of the page and updated the page revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedMinor updates include showing the glossary and the page's revision/version labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) with capitalization refinements and removal of older terms (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section with Val De Marne as a site; removed the separate 'Val De Marne Locations' entry and the 'HHS Vulnerability Disclosure' label from the footer; revision updated to v3.3.3.SummaryDifference0.3%

- Check92 days agoChange Detected- Updated page revision from v3.2.0 to v3.3.2; no changes to study content or information.SummaryDifference0.1%

Stay in the know with updates to PANDORE Clinical Trial: Pembrolizumab in Bladder Cancer
Enter your email address, and we'll notify you when there's something new on the PANDORE Clinical Trial: Pembrolizumab in Bladder Cancer page.